Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02889900 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT02889900 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 62 participants.
The verdict
NCT02889900, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell ovarian, fallopian tube or primary peritoneal carcinoma patients who have received at least 3 prior lines of chemotherapy and who do not carry deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutations.
Interventions
- DRUG cediranib and olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2017-01-17 |
| Est. Completion | 2021-03-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02889900
The ClinicalTrials.gov registry entry for NCT02889900 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cediranib and olaparib is the first listed.
NCT02889900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02889900 about?
NCT02889900 is a clinical study titled "Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer". This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell ovarian, fallopian tube or primary peritoneal carcinoma patients who hav...
What is the current status of trial NCT02889900?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2017-01-17. Estimated completion is 2021-03-16.
What interventions are being tested in trial NCT02889900?
The interventions under investigation include: cediranib and olaparib (DRUG).
Who is sponsoring clinical trial NCT02889900?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.